BiotechTube

Olaratumab + Doxorubicin + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Soft Tissue Sarcoma

Conditions

Soft Tissue Sarcoma

Trial Timeline

Sep 14, 2015 → Jun 27, 2024

NCT ID
NCT02451943

About Olaratumab + Doxorubicin + Placebo

Olaratumab + Doxorubicin + Placebo is a phase 3 stage product being developed by Eli Lilly for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02451943. Target conditions include Soft Tissue Sarcoma.

What happened to similar drugs?

2 of 14 similar drugs in Soft Tissue Sarcoma were approved

Approved (2) Terminated (3) Active (10)
✅daptomycin (up to 14 days)MerckApproved
✅linezolid + vancomycinPfizerApproved
🔄Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
❌Etoricoxib 60 mg + Etoricoxib 90 mgMerckPhase 3
🔄ridaforolimus + PlaceboMerckPhase 3
🔄Diclofenac sodiumNovartisPhase 3
🔄Doxorubicin + Ifosfamide or dacarbazine + Doxorubicin + Ifosfamide or dacarbazine + At the discretion of the investigatorNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02451943Phase 3Completed

Competing Products

20 competing products in Soft Tissue Sarcoma

See all competitors
ProductCompanyStageHype Score
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
29
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
31
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
40
Eribulin mesylateEisaiPre-clinical
26
E7389EisaiPhase 2
35
eribulin mesylateEisaiPhase 2
35
Olaratumab + Gemcitabine + Docetaxel + PlaceboEli LillyPhase 1/2
32
LY573636-sodiumEli LillyPhase 2
35
OlaratumabEli LillyPre-clinical
26
Olaratumab + DoxorubicinEli LillyPhase 1
29
Olaratumab + DoxorubicinEli LillyPhase 1
29
Olaratumab + Pembrolizumab (KEYTRUDA®)Eli LillyPhase 1
29
Olaratumab + doxorubicinEli LillyPhase 1/2
32
TrabectedinJohnson & JohnsonPre-clinical
26
Doxorubicin + Trabectedin + DexamethasoneJohnson & JohnsonPhase 1
29
Apatinib Mesylate, doxorubicin, ifosfamideJiangsu Hengrui MedicinePhase 2
31
Camrelizumab in Combination With Neoadjuvant ChemotherapyJiangsu Hengrui MedicinePhase 2
31
Durvalumab and Tremelimumab + DoxorubicinAstraZenecaPhase 2
35
Standard arm: Trabectedin in monotherapy + Experimental arm: Trabectedin + OlaparibAstraZenecaPhase 2
35
trabectedin + olaparibAstraZenecaPhase 1
29